abstract: BACKGROUND _ AIMS: Breath tests for @entity5 and/or @entity2 are used to detect small bowel @entity6 (SBBO), but false-positive results can arise from clinical conditions that accelerate small bowel transit and deliver unabsorbed @entity1 to the colon. We investigated the prevalence of false-positive results from @entity1 breath tests by also evaluating @entity0 with scintigraphy. METHODS: In a retrospective study, we reviewed data from @entity1 breath tests performed with concurrent scintigraphy on 139 @entity0 with suspected SBBO at the Medical College of Wisconsin from January 2003 through July 2013. Results from breath tests were considered abnormal (positive) if there was an increasing curve of @entity5 or @entity2 by >15 parts per million above baseline within 90 minutes. Scintigraphy was used to determine whether this increase occurred before or after the @entity1 bolus arrived at the cecum. Data from a subset of 45 @entity0 with prior upper gastrointestinal surgery were analyzed separately. RESULTS: Forty-six of the @entity0 (33%) had abnormal results from breath tests. On the basis of scintigraphy findings, 22 of these @entity0 (48%) had false-positive results, which were caused by colon fermentation of unabsorbed @entity1 . Colon fermentation caused false-positive results in 65% of @entity0 who had undergone upper gastrointestinal surgery and 13% of @entity0 without prior surgery. @entity0 with false-positive results caused by @entity3 had shorter mean oro-cecal transit times (18 minutes) compared with @entity0 with positive breath-test results because of SBBO (79 minutes) or negative results (86 minutes). CONCLUSIONS: Almost half of positive results from @entity1 breath tests are false because of @entity3 . All @entity0 with abnormal results from breath tests should be considered for @entity4 testing with concurrent scintigraphy to distinguish SBBO from @entity3 . Most @entity0 who have undergone upper gastrointestinal surgery have abnormal results from breath tests and should be assessed by using concurrent scintigraphy with the initial breath test.

title: Scintigraphy Demonstrates High Rate of False-positive Results From XXXX Breath Tests for Small Bowel @entity6 .

answer: @entity1


abstract: UNASSIGNED: A novel procedure comprising ultrasonic-assisted dynamic extraction (UADE) coupled with two countercurrent-chromatography systems (parallel countercurrent chromatography, PCCC) was developed. This technique offers the possibility for simultaneous extraction, solvent configuration, purification, and isolation of target compounds. This new approach was applied to the fractionation and purification of @entity4 from red clover. The two-phase solvent system was prepared by automating the equipment. The lower aqueous phase of the two-phase solvent system was used as the UADE solution and as the mobile phase for PCCC. After the extraction and purification steps, the purified sample was pumped into the countercurrent chromatography 1 (CCC1) column for the first isolation step. During CCC1 separation, the sample was enriched and purified and then pumped into the CCC2 column for the second isolation step. After completion of the first cycle of UADE-PCCC steps, the second-cycle experiments were performed. Using this sequence, five target compounds, @entity5 , @entity6 , @entity0 , @entity7 , and maackiain, with >95.31  % purity were successfully extracted and isolated using the two-phase solvent system of @entity1 - @entity2 - @entity3 -water (0.623:1.00:0.99:1.246, v/v). With this instrumental setup, scientific and systematic extraction and isolation of natural products was achieved, and this technique has great potential for industrial application.

title: Ultrasound-assisted dynamic extraction coupled with parallel countercurrent chromatography for simultaneous extraction, purification, and isolation of phytochemicals: application to XXXX from red clover.

answer: @entity4


abstract: CONTEXT: @entity3 has been defined as a mass composed of differentiated neuroectodermal tissue isolated from the spinal canal or cranial cavity and remains rare. This lesion has to be considered in the differential diagnosis among newborn @entity0 with classical symptoms of @entity1 , neck mass and feeding difficulties. We present a rare case of extensive parapharyngeal and skull base @entity3 in 6-month-old @entity0 who presented respiratory and feeding obstruction at birth. CASE REPORT: a six-month-old @entity0 who presented upper respiratory and feeding obstruction at birth and was using tracheostomy and @entity4 was referred to our institution. Complete surgical excision of the mass consisted of a transcervical-transparotid approach with extension to the infratemporal fossa by means of a lateral transzygomatic incision, allowing preservation of all vital neurovascular structures. The anatomopathological examination showed a solid mass with nests of neural tissue, with some neurons embedded in poorly encapsulated fibrovascular stroma, without mitotic areas, and with presence of functioning choroid plexus in the immunohistochemistry assay. Neurovascular function was preserved, thus allowing postoperative decannulation and oral feeding. Despite the large size of the mass, the @entity0 has completed one year and six months of follow-up without complications or recurrence. @entity3 needs to be considered in diagnosing @entity2 . Surgical treatment is the best choice and should be performed on clinically stable @entity0 . An algorithm to guide the differential diagnosis and improve the treatment was proposed.

title: Extensive parapharyngeal and skull base XXXX ; a challenge for differential diagnosis and treatment: case report.

answer: @entity3


abstract: BACKGROUND: Despite the establishment of effective medical therapies in @entity6 , @entity4 remains one of the most common health problem in Tunisia. Various operations have been attempted, which may lead to postoperative morbidity. @entity2 is the most common complications. AIM: to determine the predictive factor of @entity2 after gastrojejunostomy for @entity6 . METHODS: We carried out a retrospective study to evaluate the postoperative recovery of the motility of the upper gastrointestinal tract after gastrojejunostomy for @entity6 . During the 9- year study, 138 @entity0 underwent operations for @entity6 . Among the @entity0 , 116 (84,1%) were treated with gastrojejunostomy. Descriptive statistics, univariate and multivariate analyses were performed. RESULTS: The mean age of @entity0 was 47.85 years (range: 19- 92years) and most. Were male (84, 5 %). Ninety two (79.3%) @entity0 had a documented history of @entity6 . The duration of symptoms ranged from 10 to 372 days (mean: 135.86 days). Eighty two (71%) @entity0 were operated on through laparotomy. Laparoscopic procedure was performed in 29% of the @entity0 . There was no operative mortality. Perioperative morbidity occurred in 12.4% (14 @entity0 ). @entity2 occurred in 12 @entity0 (10.3%). It was treated by nasogastric aspiration and prokinetics. By univariate analysis; @entity1 (0,010), @entity5 (0,049), ASA class (0.05) were all statistically associated with @entity2 in this series. Multivariate logistic regression analysis (table 2) showed that the @entity5 (0,009), ASA class (0.02) were the main predictors of @entity2 after gastrojejunostomy for @entity6 in the followed @entity0 . CONCLUSION: @entity2 is the most common complications after gastrojejunostomy for pyloric adult stenosis. Surgery must be preceded by careful medical preparation. It is more likely to occur in @entity0 with an ASA class 2 or greater. Those @entity0 should be considered for other treatment options, such as @entity3 .

title: Predictive factors of Gastrointestinal motility Dysfunction after gastrojejunostomy for XXXX .

answer: @entity6


abstract: PURPOSE: @entity5 is characterised by a sense of unreality about the self [depersonalization (DP)] and/or the outside world [derealization (DR)]. Prevalence estimates vary widely. Little is known about childhood antecedents of the disorder although @entity4 is thought to play a role. METHODS: Longitudinal data from 3,275 @entity0 of a UK population-based birth cohort (the MRC National Survey of Health and Development) were used to: (1) assess the prevalence of @entity5 at age 36, measured by the Present State Examination (PSE); and (2) examine the effects of a range of socio-demographic, childhood adversity and emotional responses as potential risk factors for DP. RESULTS: Thirty three survey members were classified with DP, yielding a prevalence of 0.95% [95% confidence intervals (CI) 0.56-1.34]. There were no associations with socio-economic status, parental @entity2 or divorce; self-reported accidents, @entity3 , tendency to daydream or reactions to criticism. However, teacher-estimated childhood @entity1 was a strong independent predictor of adult depersonalization, and there were strong cross-sectional relationships between DP and @entity1 and @entity3 caseness. CONCLUSIONS: To our knowledge this is the first study assessing nationwide prevalence of the @entity5 and uses longitudinal data to explore childhood risk factors for adult DP. The prevalence of adult DP was slightly lower than reported by other surveys. The study found that childhood @entity1 was the only significant predictor of the adult @entity5 , supporting the view that depersonalisation disorder forms part of the spectrum of responses to @entity1 .

title: Prevalence and childhood antecedents of XXXX in a UK birth cohort.

answer: @entity5


abstract: RATIONALE: Response inhibition, a primary symptom of many @entity2 , is mediated through a complex neuropharmacological network that involves @entity4 , @entity3 , @entity8 , @entity6 , and cannabinoid mechanisms. Recently, we identified an opioidergic contribution to response inhibition by showing that deletion of mu or delta opioid receptors in @entity0 alters motor impulsivity. OBJECTIVES: We investigated this phenomenon further by testing whether pharmacological activation of opioid receptors disrupts the ability to inhibit a motor response. METHODS: Long-Evans @entity1 were trained to withhold a lever-pressing response for @entity5 until a discriminative stimulus (lever light) was presented. The delay to the discriminative stimulus (1 to 60  s) was varied, so animals could not predict, on any given trial, the length of the pre-response phase. Motor impulsivity was assessed as the inability to inhibit lever pressing prior to the discriminative stimulus. @entity1 were tested following an injection of the mu opioid receptor agonist @entity7 (0, 0.5, 1, 2, 4, 6, 8, or 10  mg/kg) or the delta receptor agonist @entity10 (0, 2.5, 5, or 10  mg/kg). RESULTS: @entity10 (10  mg/kg) increased premature responses and locomotor activity, but had no effect on the speed of responding or non-reinforced presses. The @entity10 -induced decrease in accuracy was blocked by the delta opioid receptor antagonist @entity9 . @entity7 had no effect on accuracy but increased locomotor activity (2  mg/kg). CONCLUSIONS: These findings point to a role for delta, but not mu, opioid receptors in disinhibition as measured in the response inhibition task. The results appear to contradict those of previous opioid receptor deletion studies; possible sources of these discrepant results are discussed.

title: Effects of delta opioid receptors activation on a response inhibition task in XXXX .

answer: @entity1


abstract: BACKGROUND: Left upper division segmentectomy is one of the major pulmonary procedures; however, it is sometimes difficult to completely dissect interlobar lymph nodes. We attempted to clarify the prognostic importance of hilar and mediastinal nodes, especially of interlobar lymph nodes, in @entity0 with primary @entity4 ( @entity4 ) located in the left upper division. METHODS: We retrospectively studied @entity0 with primary @entity4 undergoing surgical pulmonary resection (at least lobectomy) with radical lymphadenectomy. The representative evaluation of therapeutic value from the lymph node dissection was determined using Sasako's method. This analysis was calculated by multiplying the frequency of @entity1 to the station and the 5-year survival rate of the @entity0 with @entity1 to the station. RESULTS: We enrolled 417 @entity0 (237 @entity0 , 180 @entity0 ). @entity2 were located in the lingular lobe and at the upper division of left upper lobe in 69 and 348 @entity0 , respectively. The pathological nodal statuses were pN0 in 263 @entity0 , @entity5 in 70 @entity0 , and @entity3 in 84 @entity0 . Lymph nodes #11 and #7 were significantly correlated with differences in node involvement in @entity0 with @entity4 . Among those with left upper division @entity4 , the 5-year overall survival in @entity5 was 31.5% for #10, 39.3% for #11, and 50.4% for #12U. The involvement of node #11 was 1.89-fold higher in the anterior segment than that in the apicoposterior segment. The therapeutic index of estimated benefit from lymph node dissection for #11 was 3.38, #4L was 1.93, and the aortopulmonary window was 4.86 in primary left upper division @entity4 . CONCLUSIONS: Interlobar node involvement is not rare in left upper division @entity4 , occurring in >20% cases. Furthermore, dissection of interlobar nodes was found to be beneficial in @entity0 with left upper division @entity4 .

title: Lymph Node XXXX and Prognosis in Left Upper Division Non-Small Cell Lung Cancers: The Impact of Interlobar Lymph Node @entity1 .

answer: @entity1


abstract: BACKGROUND: Left upper division segmentectomy is one of the major pulmonary procedures; however, it is sometimes difficult to completely dissect interlobar lymph nodes. We attempted to clarify the prognostic importance of hilar and mediastinal nodes, especially of interlobar lymph nodes, in @entity0 with primary @entity4 ( @entity4 ) located in the left upper division. METHODS: We retrospectively studied @entity0 with primary @entity4 undergoing surgical pulmonary resection (at least lobectomy) with radical lymphadenectomy. The representative evaluation of therapeutic value from the lymph node dissection was determined using Sasako's method. This analysis was calculated by multiplying the frequency of @entity1 to the station and the 5-year survival rate of the @entity0 with @entity1 to the station. RESULTS: We enrolled 417 @entity0 (237 @entity0 , 180 @entity0 ). @entity2 were located in the lingular lobe and at the upper division of left upper lobe in 69 and 348 @entity0 , respectively. The pathological nodal statuses were pN0 in 263 @entity0 , @entity5 in 70 @entity0 , and @entity3 in 84 @entity0 . Lymph nodes #11 and #7 were significantly correlated with differences in node involvement in @entity0 with @entity4 . Among those with left upper division @entity4 , the 5-year overall survival in @entity5 was 31.5% for #10, 39.3% for #11, and 50.4% for #12U. The involvement of node #11 was 1.89-fold higher in the anterior segment than that in the apicoposterior segment. The therapeutic index of estimated benefit from lymph node dissection for #11 was 3.38, #4L was 1.93, and the aortopulmonary window was 4.86 in primary left upper division @entity4 . CONCLUSIONS: Interlobar node involvement is not rare in left upper division @entity4 , occurring in >20% cases. Furthermore, dissection of interlobar nodes was found to be beneficial in @entity0 with left upper division @entity4 .

title: Lymph Node @entity1 and Prognosis in Left Upper Division Non-Small Cell Lung Cancers: The Impact of Interlobar Lymph Node XXXX .

answer: @entity1


abstract: BACKGROUND: Laparoscopic resection is considered the treatment of choice for @entity2 . Occasionally, it is necessary to perform an intraoperative gastroscopy to localize the lesion. There are no data in the literature addressing the factors that can predict when a combined laparoscopic-endoscopic approach will be needed. METHODS: A retrospective cohort study using a prospectively collected database was conducted. From January 2005 to December 2013, all the @entity0 undergoing a laparoscopic gastric resection for @entity1 irresectable by endoscopy were reviewed. Potential predictive factors for the need of an intraoperative endoscopy were analyzed. RESULTS: Thirty-eight consecutive @entity0 (22 @entity0 and 16 @entity0 ) with a mean age of 67 (41-86) years underwent laparoscopic gastric resection for @entity1 . Fourteen (36.8  %) @entity0 required intraoperative endoscopic assessment. The only significant factors related to the need of endoscopic assessment during surgery were @entity1 growth pattern (P  =  0.002) and size (P  =  0.001). CONCLUSIONS: An accurate description of @entity1 growth pattern and size by EUS is recommended in the preoperative assessment of @entity2 . Small @entity1 ( <=18  mm) with an intraluminal growth may need a combined endoscopic-assisted laparoscopic management.

title: Endoscopic-assisted laparoscopic resection for XXXX .

answer: @entity2


abstract: UNASSIGNED: Disease modifying therapies (DMTs) reduce the frequency of relapses and accumulation of disability in @entity1 ( @entity1 ). Long-term persistence with treatment is important to optimize treatment benefit. This long-term, cohort study was conducted at the Calgary @entity1 Clinic. All consenting adults with relapsing-remitting @entity1 who started either @entity2 (GA) or interferon-b 1a/1b ( @entity3 ) between January 1st, 1996 and July 1st, 2011 were included. Follow-up continued to February 1st, 2014. Time-to-discontinuation of the initial and subsequently-prescribed DMTs (switches) was analysed using Kaplan-Meier survival analyses. Group differences were compared using log-rank tests and multivariable Cox regression models. Analysis included 1471 @entity0 ; 906 were initially prescribed GA and 565 were initially prescribed @entity3 . Follow-up information was available for 87%; 29 (2%) were lost to follow-up and 160 (11%) moved from Southern Alberta while still using @entity4 . Median time-to-discontinuation of all injectable DMTs was 11.1 years. @entity0 with greater disability at treatment initiation, those who started treatment before age 30, and those who started between 2006 and 2011 were more likely to discontinue use of all injectable DMTs. Median time-to-discontinuation of the initial @entity4 was 8.6 years. Those initially prescribed GA remained on treatment longer. Of 610 @entity0 who discontinued injectable @entity4 , 331 (54%) started an oral @entity4 , or a second-line @entity4 , or resumed injectable @entity4 after 90 days. Persistence with injectable DMTs was high in this long-term population-based study. Most @entity0 who discontinued injectable @entity4 did not remain untreated. Further research is required to understand treatment outcomes and outcomes after stopping @entity4 .

title: Long-Term Persistence with Injectable Therapy in Relapsing-Remitting XXXX : An 18-Year Observational Cohort Study.

answer: @entity1


abstract: BACKGROUND: @entity2 status during prenatal brain development may influence risk of @entity1 ( @entity1 ) symptoms in childhood. However, there are no prospective studies addressing this hypothesis. We aimed to examine whether maternal @entity2 status in pregnancy is associated with risk of @entity1 -like symptoms in offspring. METHODS: We conducted a prospective study analyzing data from 1,650 mother- @entity0 pairs from five birth cohorts embedded in the INMA Project (Spain, 1997-2008). Maternal @entity2 status in pregnancy was estimated by measuring plasma concentration of @entity5 [ @entity4 ] at 13 weeks of gestation. @entity0 were assessed by teachers for @entity1 -like symptoms at ages 4-5 years using the Diagnostic and Statistical Manual of Mental Disorders @entity1 form list. RESULTS: After adjustment, the number of total @entity1 -like symptoms in @entity0 decreased by 11% per 10   ng/ml increment of maternal @entity4 concentration (incidence rate ratio [IRR] = 0.89; 95% confidence interval [CI] = 0.80, 0.98). Similarly, the number of symptoms in the @entity1 subscales decreased in relation to higher maternal @entity4 concentration (IRR per 10   ng/ml increment = 0.89; 95% CI = 0.79, 0.99 for the inattention scale; and IRR = 0.88; 95% CI = 0.78, 0.99 for the @entity3 -impulsivity scale). Using diagnostic criteria, we found an association of increasing maternal @entity4 with a lower risk of @entity1 DSM-IV (relative risk ratio per 10   ng/ml increment = 0.87; 95% CI = 0.72, 1.06) and ICD-10 @entity1 (relative risk ratio = 0.72; 95% CI = 0.49, 1.04) in @entity0 . CONCLUSION: Higher maternal circulating levels of @entity4 in pregnancy are associated with lower risk of developing @entity1 -like symptoms in childhood.

title: XXXX in Pregnancy and Attention Deficit Hyperactivity Disorder-like Symptoms in Childhood.

answer: @entity2


abstract: BACKGROUND: @entity0 with FIGO stage @entity4 have a poor but non-uniform prognosis. This study aimed to compare the survival of @entity0 with @entity2 ( @entity2 ) and clear cell or mucinous @entity2 (non- @entity2 ). METHODS: Data for 223 @entity0 who underwent surgery between 1987 and 2010 and were diagnosed by centralized pathology review and were retrospectively analysed. The @entity0 included 169 with @entity2 @entity2 and 54 with non- @entity2 @entity2 . RESULTS: The median overall survivals (OSs) of the @entity2 and non- @entity2 groups were 3.1 and 0.9 years, respectively (P<0.001). Six @entity0 (2.7%), all with non- @entity2 @entity2 , died within 6 weeks after the initial surgery. Multivariate OS analysis revealed that performance status, @entity3 , metastatic sites, no debulking surgery, and non- @entity2 @entity2 were independent poor prognostic factors. For @entity0 with non- @entity2 @entity2 , prognosis was more favourable for single-organ @entity1 , except for liver or distant lymph nodes, no @entity3 , and resection of @entity1 (median OS: 4.1, 4.6, and 2.6 years, respectively). CONCLUSIONS: In @entity4 , non- @entity2 @entity2 are associated with a significantly poorer prognosis and higher rates of early mortality compared to @entity2 @entity2 . Therefore, careful management and development of new strategies are required.

title: Prognostic value of histological type in XXXX : a retrospective analysis of 223 @entity0 .

answer: @entity4


abstract: BACKGROUND: @entity0 with FIGO stage @entity4 have a poor but non-uniform prognosis. This study aimed to compare the survival of @entity0 with @entity2 ( @entity2 ) and clear cell or mucinous @entity2 (non- @entity2 ). METHODS: Data for 223 @entity0 who underwent surgery between 1987 and 2010 and were diagnosed by centralized pathology review and were retrospectively analysed. The @entity0 included 169 with @entity2 @entity2 and 54 with non- @entity2 @entity2 . RESULTS: The median overall survivals (OSs) of the @entity2 and non- @entity2 groups were 3.1 and 0.9 years, respectively (P<0.001). Six @entity0 (2.7%), all with non- @entity2 @entity2 , died within 6 weeks after the initial surgery. Multivariate OS analysis revealed that performance status, @entity3 , metastatic sites, no debulking surgery, and non- @entity2 @entity2 were independent poor prognostic factors. For @entity0 with non- @entity2 @entity2 , prognosis was more favourable for single-organ @entity1 , except for liver or distant lymph nodes, no @entity3 , and resection of @entity1 (median OS: 4.1, 4.6, and 2.6 years, respectively). CONCLUSIONS: In @entity4 , non- @entity2 @entity2 are associated with a significantly poorer prognosis and higher rates of early mortality compared to @entity2 @entity2 . Therefore, careful management and development of new strategies are required.

title: Prognostic value of histological type in @entity4 : a retrospective analysis of 223 XXXX .

answer: @entity0


abstract: BACKGROUND: The cyclin-dependent kinase (CDK) inhibitor @entity4 (Kip)   is downregulated in a majority of @entity0 @entity1 due to ectopic proteolysis by the ubiquitin-proteasome pathway. The expression of @entity4 is subject to multiple mechanisms of control involving several transcription factors, kinase pathways and at least three different ubiquitin ligases (SCF(SKP)  , KPC, @entity10 ), which regulate @entity4 transcription, translation, protein stability and subcellular localization. Using a chemical genetics approach, we have asked whether this control network can be modulated by small molecules such that @entity4 protein expression is restored in @entity1 cells. RESULTS: We developed a cell-based assay for measuring the levels of endogenous nuclear @entity4 in a high throughput screening format employing @entity3 cells engineered to overexpress @entity8 . The assay platform was optimized to Z' factors of 0.48 - 0.6 and piloted by screening a total of 7368 chemical compounds. During the course of this work, we discovered two small molecules of previously unknown biological activity, SMIP001 and SMIP004, which increase the nuclear level of @entity4 at low micromolar concentrations. SMIPs (small molecule inhibitors of @entity4 depletion) also upregulate @entity5 ( @entity9 )  , inhibit cellular @entity7 activity, induce G1 delay, inhibit colony formation in soft agar and exhibit preferential @entity2 in LNCaP cells relative to normal @entity0 fibroblasts. Unlike SMIP001, SMIP004 was found to downregulate @entity8 and to stabilize @entity4 , although neither SMIP is a proteasome inhibitor. Whereas the screening endpoint - nuclear @entity4 - was robustly modulated by the compounds, SMIP-mediated cell cycle arrest and apoptosis were not strictly dependent on @entity4 and @entity5 - a finding that is explained by parallel inhibitory effects of SMIPs on positive cell cycle regulators, including cyclins E and A, and @entity6 . CONCLUSIONS: Our data provide proof-of-principle that the screening platform we developed, using endogenous nuclear @entity4 as an endpoint, presents an effective means of identifying bioactive molecules with @entity1 selective antiproliferative activity. This approach, when applied to larger and more diverse sets of compounds with refined drug-like properties, bears the potential of revealing both unknown cellular pathways globally impinging on @entity4 and novel leads for chemotherapeutics targeting a prominent molecular defect of @entity0 @entity1 .

title: Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in XXXX cells.

answer: @entity3


abstract: BACKGROUND: Now the treatment of @entity3 ( @entity3 ) @entity0 with brain @entity1 is not a standard program. The aim of this study is to summarize the factors related to survival of @entity0 with brain metastases from @entity3 . METHODS: A total of 111 @entity3 @entity0 with brain metastases (from September 1995-May 2004) were defined as symptomatic group (37 @entity0 ) and asymptomatic group (74 @entity0 ) according to central nervous system (CNS) symptoms. The @entity0 in the symptomatic group were given whole brain radiation therapy (WBRT, DT 30-40Gy/20f) first, and then received @entity2 -based chemotherapy. The @entity0 in the asymptomatic group were given @entity2 -based chemotherapy first, and then received WBRT. During the treatment, 49 @entity0 received chemotherapy of BCNU or @entity4 irregularly. RESULTS: The median survival time was 11 months. The 1-and 2-year survival rate was 40.79% and 13.26% respectively. The survival time was not significantly different between the symptomatic group and asymptomatic group. Median chemotherapy of asymptomatic group was 3 cycles (1-6 cycles) before WBRT. Those @entity0 who received 3 or 4 cycles of chemotherapy before WBRT had better survival (P= 0.0188 , P=0.0035). The treatment of BCNU or @entity4 was a benefit factor for survival (P=0.0219) in asymptomatic group. The hematologic toxicity of grade III or IV was not significantly different between the two groups (P > 0.05). The number of brain @entity1 (P=0.000), extracranial @entity1 (P=0.022) and WHO performance status (P=0.001) were independent prognostic factors. CONCLUSIONS: The @entity0 with asymptomatic brain metastases receive 3-4 cycles of chemotherapy before WBRT may be reasonable. During the therapy, the @entity0 with administration of BCNU or @entity4 may have survival benefit.

title: [Treatment and prognosis of brain metastases from XXXX : A retrospective study].

answer: @entity3


abstract: INTRODUCTION: Unruptured @entity2 (UIAs) are frequently detected in noninvasive imaging studies such as computed tomography angiography (CTA) or magnetic resonance angiography (MRA). If small, UIAs are observed in these modalities in order to detect growth or shape change, but there are many questions about proper protocol of the follow-up. AIM: To assess changes of small (< 7 mm) UIAs dome size and shape in repeated CTA studies as predictors of growth and @entity1 . MATERIAL AND METHODS: One hundred and ten UIAs (10 posterior circulation) in 70 @entity0 (55 @entity0 ) were observed, with a cumulative observation time of 333.32 years. @entity3 ' dome and neck perpendicular dimensions were measured in the first and the last CTA study at least twice with the developed application. Confidence intervals (CI) for measurements and dome shape parameters were calculated. For @entity3 ruptured during follow-up intermediate studies were analyzed. @entity0 ' clinical information was recorded. The @entity3 growth detection algorithm integrated CI and spatial resolution of the CT scanner. RESULTS: Twenty-three @entity3 increased in volume, 10 in height and 14 in dome width. Volume increased in 90% of cases of height and 93% of width increase. Posterior circulation @entity3 grew faster than anterior ones (p < 0.003), but calculated time to significant size increase (eT) did not differ between the groups due to higher CI in the posterior circulation. Analysis of eT with Kaplan-Meier curves showed that 75% of growing @entity3 could be detected in the first 3 years of observation. During the follow-up 3 @entity3 bled, and they grew faster than other growing @entity3 . Two of the bleeding @entity3 formed daughter sacs. CONCLUSIONS: Dome volume assessment is superior to single dimension assessment in @entity3 growth detection. Confidence intervals assessment helps to avoid overestimation of growth. Seventy-five percent of growing @entity3 could be detected in the first 3 years of observation. Daughter sac formation and fast increase in size are strong predictors of @entity4 .

title: Changes of size and shape of small, unruptured XXXX in repeated computed tomography angiography studies.

answer: @entity2


abstract: INTRODUCTION: The aim of this study was to evaluate the feasibility of epidermal growth factor receptor- @entity7 kinase inhibitor ( @entity4 -TKI) and @entity4 mutation frequency in advanced @entity5 based on the data from our hospital. MATERIAL AND METHODS: The clinical data of 102 @entity0 with advanced @entity5 who were admitted to Zhejiang Cancer Hospital from January 2007 to December 2011 were retrospectively analyzed. Survival analysis was evaluated by the Kaplan-Meier method. The @entity4 mutations were assessed in some of the @entity0 using the pyrosequencing assay. RESULTS: Nine @entity0 (8.8%) showed a partial response (PR), 28 (27.5%) achieved @entity1 ( @entity1 ), and 65 (63.7%) had @entity2 ( @entity2 ). The disease control rate was 36.3% and the median progression-free survival (PFS) was 1.93 months (95% CI: 1.57-2.29). The PFS in @entity0 who obtained disease control in the prior TKI was 8.63 months and 1.37 months in the disease progression cases (p < 0.001). No statistical differences in PFS were observed between @entity8 and @entity6 (2.0 months vs. 1.87 months, p = 0.76). The @entity3 associated with @entity4 -TKI were generally acceptable. In 74 @entity0 with adequate specimens for molecular analysis, 4 (5.4%) had @entity4 mutations (2 with deletions within exon 19 and 2 with @entity9 mutation in exon 21). CONCLUSIONS: The @entity4 - @entity7 kinase inhibitor seems to be a potential therapeutic option for treatment of advanced @entity5 @entity0 . @entity6 and @entity8 had a similar efficacy in advanced @entity5 . The frequency of @entity4 mutation was about 5.4% in our single hospital data.

title: Efficacy of @entity8 or @entity6 in @entity0 with XXXX .

answer: @entity5


abstract: INTRODUCTION: The aim of this study was to evaluate the feasibility of epidermal growth factor receptor- @entity7 kinase inhibitor ( @entity4 -TKI) and @entity4 mutation frequency in advanced @entity5 based on the data from our hospital. MATERIAL AND METHODS: The clinical data of 102 @entity0 with advanced @entity5 who were admitted to Zhejiang Cancer Hospital from January 2007 to December 2011 were retrospectively analyzed. Survival analysis was evaluated by the Kaplan-Meier method. The @entity4 mutations were assessed in some of the @entity0 using the pyrosequencing assay. RESULTS: Nine @entity0 (8.8%) showed a partial response (PR), 28 (27.5%) achieved @entity1 ( @entity1 ), and 65 (63.7%) had @entity2 ( @entity2 ). The disease control rate was 36.3% and the median progression-free survival (PFS) was 1.93 months (95% CI: 1.57-2.29). The PFS in @entity0 who obtained disease control in the prior TKI was 8.63 months and 1.37 months in the disease progression cases (p < 0.001). No statistical differences in PFS were observed between @entity8 and @entity6 (2.0 months vs. 1.87 months, p = 0.76). The @entity3 associated with @entity4 -TKI were generally acceptable. In 74 @entity0 with adequate specimens for molecular analysis, 4 (5.4%) had @entity4 mutations (2 with deletions within exon 19 and 2 with @entity9 mutation in exon 21). CONCLUSIONS: The @entity4 - @entity7 kinase inhibitor seems to be a potential therapeutic option for treatment of advanced @entity5 @entity0 . @entity6 and @entity8 had a similar efficacy in advanced @entity5 . The frequency of @entity4 mutation was about 5.4% in our single hospital data.

title: Efficacy of @entity8 or XXXX in @entity0 with @entity5 .

answer: @entity6


abstract: INTRODUCTION: The aim of this study was to evaluate the feasibility of epidermal growth factor receptor- @entity7 kinase inhibitor ( @entity4 -TKI) and @entity4 mutation frequency in advanced @entity5 based on the data from our hospital. MATERIAL AND METHODS: The clinical data of 102 @entity0 with advanced @entity5 who were admitted to Zhejiang Cancer Hospital from January 2007 to December 2011 were retrospectively analyzed. Survival analysis was evaluated by the Kaplan-Meier method. The @entity4 mutations were assessed in some of the @entity0 using the pyrosequencing assay. RESULTS: Nine @entity0 (8.8%) showed a partial response (PR), 28 (27.5%) achieved @entity1 ( @entity1 ), and 65 (63.7%) had @entity2 ( @entity2 ). The disease control rate was 36.3% and the median progression-free survival (PFS) was 1.93 months (95% CI: 1.57-2.29). The PFS in @entity0 who obtained disease control in the prior TKI was 8.63 months and 1.37 months in the disease progression cases (p < 0.001). No statistical differences in PFS were observed between @entity8 and @entity6 (2.0 months vs. 1.87 months, p = 0.76). The @entity3 associated with @entity4 -TKI were generally acceptable. In 74 @entity0 with adequate specimens for molecular analysis, 4 (5.4%) had @entity4 mutations (2 with deletions within exon 19 and 2 with @entity9 mutation in exon 21). CONCLUSIONS: The @entity4 - @entity7 kinase inhibitor seems to be a potential therapeutic option for treatment of advanced @entity5 @entity0 . @entity6 and @entity8 had a similar efficacy in advanced @entity5 . The frequency of @entity4 mutation was about 5.4% in our single hospital data.

title: Efficacy of XXXX or @entity6 in @entity0 with @entity5 .

answer: @entity8


abstract: INTRODUCTION: The aim of this study was to evaluate the feasibility of epidermal growth factor receptor- @entity7 kinase inhibitor ( @entity4 -TKI) and @entity4 mutation frequency in advanced @entity5 based on the data from our hospital. MATERIAL AND METHODS: The clinical data of 102 @entity0 with advanced @entity5 who were admitted to Zhejiang Cancer Hospital from January 2007 to December 2011 were retrospectively analyzed. Survival analysis was evaluated by the Kaplan-Meier method. The @entity4 mutations were assessed in some of the @entity0 using the pyrosequencing assay. RESULTS: Nine @entity0 (8.8%) showed a partial response (PR), 28 (27.5%) achieved @entity1 ( @entity1 ), and 65 (63.7%) had @entity2 ( @entity2 ). The disease control rate was 36.3% and the median progression-free survival (PFS) was 1.93 months (95% CI: 1.57-2.29). The PFS in @entity0 who obtained disease control in the prior TKI was 8.63 months and 1.37 months in the disease progression cases (p < 0.001). No statistical differences in PFS were observed between @entity8 and @entity6 (2.0 months vs. 1.87 months, p = 0.76). The @entity3 associated with @entity4 -TKI were generally acceptable. In 74 @entity0 with adequate specimens for molecular analysis, 4 (5.4%) had @entity4 mutations (2 with deletions within exon 19 and 2 with @entity9 mutation in exon 21). CONCLUSIONS: The @entity4 - @entity7 kinase inhibitor seems to be a potential therapeutic option for treatment of advanced @entity5 @entity0 . @entity6 and @entity8 had a similar efficacy in advanced @entity5 . The frequency of @entity4 mutation was about 5.4% in our single hospital data.

title: Efficacy of @entity8 or @entity6 in XXXX with @entity5 .

answer: @entity0


abstract: The @entity4 ( @entity4 ) is rare in adulthood. Diagnosis is made by clinical suspicion and physical findings such as blood pressure difference between the upper and lower extremities, pulse delay in the femoral artery, and systolic murmur over the thoracic spine. The @entity4 in adulthood and in @entity0 with associated @entity2 is challenging and different complications even with proper treatment can occur. Covered stents are indicated in concomitant @entity2 , older age, and @entity4 . A 26-year-old male with resistant @entity1 due to a @entity4 diagnosed by computed tomography angiography referred to our center for an attempted stent implantation. Cardiac catheterization and aortography revealed a long @entity4 after the origin of the left subclavian artery with a 60 mmHg gradient. Moreover, there was a large @entity2 in the site of the @entity4 . Under general anesthesia and fluoroscopic guidance, two balloon-expandable covered Cheatham- @entity3 stents (size 18 in 44 millimeters and size 18 in 50 millimeters) were successfully implanted across the @entity4 with no residual gradient. On 2 years' follow-up, the @entity0 had no symptoms except for mild @entity1 . In this @entity0 , the use of a covered stent within the @entity2 was safe and effective.

title: Percutaneous treatment for XXXX with covered stenting: a case report.

answer: @entity2


abstract: UNASSIGNED: @entity5 is one of the most common @entity1 of the major salivary glands. It can also occur in the minor salivary glands, which exist in the nasal cavity. Intranasal @entity5 usually originates from glands of the nasal septum mucosa. We present the results of endoscopic endonasal surgery of this pathology. The aim of the study was to present the endoscopic technique for nasal septum @entity5 surgery. The retrospective examination of 3 @entity0 was performed. There were 2 @entity0 and 1 @entity0 . Age ranged from 15 to 46 years. All the @entity0 presented with nasal obstruction and occasional @entity2 for at least for 6 months. We performed endoscopic surgery to remove the @entity1 . In all cases we dissected the septal perichondrium to achieved free margins of the @entity1 . The microscopic examination revealed an epithelial and @entity4 with tubular structures composed of two cell layers, ducts, and a solid area found in a loose myxochondroid area. Additionally, immunohistochemical staining was performed using antibodies against cytokeratin, Ki-67, and @entity3 . @entity0 ' postoperative course was uneventful, and no complications were encountered. No recurrence was present during @entity0 ' postoperative visits. Nasal benign @entity5 is a rare @entity1 which should be taken into consideration in the nasal cavity during surgery. The correct histological diagnosis can be confirmed by additional histological studies. Endoscopic endonasal surgery is reserved for small @entity1 .

title: Rare benign XXXX of the nose: short study and literature review.

answer: @entity5


abstract: STUDY DESIGN: Prospective study. PURPOSE: To determine the role of routine preoperative magnetic resonance imaging (MRI) to detect the incidence and risk factors for @entity2 in @entity0 with @entity6 . OVERVIEW OF LITERATURE: The incidence and risk factors for @entity2 in @entity0 with @entity6 are controversial, and the indications for preoperative MRI in these @entity0 vary among centers. METHODS: Information on @entity0 with @entity6 who were surgical candidates over 10 years (age at presentation, sex, magnitude and apex of major curve, @entity2 detected by MRI, and neurological examination results) were recorded, the @entity0 were grouped according to the @entity2 , and the data were analyzed. RESULTS: Of the 271 @entity0 with @entity6 , 27 had @entity5 (9.9%). Of these 27 @entity0 , 14 (52%) underwent a neurosurgical procedure. Significant differences were observed in the frequency of @entity1 onset and male sex (p<0.05) between the group of @entity0 with @entity5 on preoperative MRI and those who did not have a @entity4 . No difference was detected in the magnitude or direction of the curve. CONCLUSIONS: @entity5 in @entity0 with @entity6 and a normal neurological examination were highly frequent (9.9%). Missing these abnormalities before surgery could inflict @entity3 . The incidence of @entity5 was higher in male @entity0 and in those with early onset disease. Thus, MRI is essential for all @entity0 with @entity6 who require medical intervention.

title: The Role of Routine Preoperative Magnetic Resonance Imaging in XXXX : A Ten Years Review.

answer: @entity6


abstract: BACKGROUND: @entity0 subtype, determined by expression of @entity2 / @entity3 receptor (ER/PR) and @entity1 @entity4 , is predictive for prognosis. The importance of subtype to locoregional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant radiotherapy (RT). METHODS: We retrospectively identified 160- @entity0 @entity1 registered at Columbia University Medical Center from 1999 to 2012 treated with NAC, surgery and adjuvant RT. RESULTS: @entity1 were grouped by receptor status: hormone receptor positive (HR+) [(ER or PR+)/ @entity4 -; n  =  75], @entity4 + (n  =  46), or triple-negative (TNBC) [ER (-) PR (-) @entity4 (-); n  =  36]. The median follow-up was 28  months. 92.0% received an @entity7 - @entity5 based NAC and 80.4% of @entity4 + @entity1 received trastuzumab. All underwent surgical resection followed by RT. 15.6% had a pathologic complete response (pCR): 26% of @entity4 +, 5% of HR+, and 25% of @entity8 . The actuarial rate of @entity6 was 13.8% for the entire cohort, with equivalent rates by subtypes in non-pCR @entity1 . The overall rate of LRR was 8%. However, the LRR rate was significantly higher for TNBC @entity1 (22.2%) than @entity4 + (5.6%) (p  =  0.025) or HR+ (3.0%) (p  =  0.037) in non-pCR group. In the pCR group, two @entity1 had recurrence; one LRR and one a @entity6 , both had TNBC. All LRR occurred in or near the radiation field. CONCLUSIONS: TNBC @entity1 with  <  pCR to NAC have a significantly higher LRR rate as compared to other subtypes even with surgery and adjuvant RT. Our data support a need to further intensify local therapy in TNBC @entity1 .

title: Higher locoregional recurrence rate for triple-negative XXXX following neoadjuvant chemotherapy, surgery and radiotherapy.

answer: @entity0


abstract: Background. Acute @entity6 has been documented in experimental models of @entity2 -reperfusion @entity3 and is usually investigated by magnetic resonance imaging. Purpose. We describe a case of acute ventricular wall thickening documented by echocardiography in a @entity0 developing @entity5 and @entity12 . Case Description. A 40-year-old @entity0 , with a history of mixed connective tissue disease, was admitted with @entity1 and @entity4 . She developed @entity7 @entity5 and @entity9 were consistent with a @entity12 . Echocardiography revealed an impressive diffuse thickening of the whole myocardium (interventricular septum 18   mm; posterior wall 16   mm) with diffuse @entity11 and markedly reduced left ventricular ejection fraction (31%). There was also a moderate @entity10 . Echocardiography was normal two months before. The @entity0 died from @entity8 . Macroscopic and microscopic examination of the heart suggested that the ventricular wall thickening was induced by oedematous changes, together with an excess of inflammatory cells. Conclusion. Acute ventricular wall thickening that corresponded to @entity6 as a first hypothesis was observed at echocardiography during the course of @entity5 complicated by @entity12 .

title: Acute ventricular wall thickening: XXXX , @entity12 , or myocarditis?

answer: @entity5


abstract: Background. Acute @entity6 has been documented in experimental models of @entity2 -reperfusion @entity3 and is usually investigated by magnetic resonance imaging. Purpose. We describe a case of acute ventricular wall thickening documented by echocardiography in a @entity0 developing @entity5 and @entity12 . Case Description. A 40-year-old @entity0 , with a history of mixed connective tissue disease, was admitted with @entity1 and @entity4 . She developed @entity7 @entity5 and @entity9 were consistent with a @entity12 . Echocardiography revealed an impressive diffuse thickening of the whole myocardium (interventricular septum 18   mm; posterior wall 16   mm) with diffuse @entity11 and markedly reduced left ventricular ejection fraction (31%). There was also a moderate @entity10 . Echocardiography was normal two months before. The @entity0 died from @entity8 . Macroscopic and microscopic examination of the heart suggested that the ventricular wall thickening was induced by oedematous changes, together with an excess of inflammatory cells. Conclusion. Acute ventricular wall thickening that corresponded to @entity6 as a first hypothesis was observed at echocardiography during the course of @entity5 complicated by @entity12 .

title: Acute ventricular wall thickening: @entity5 , XXXX , or myocarditis?

answer: @entity12


abstract: A combined therapy approach to @entity5 and middle ear has been developed. A technique of external canal resection and gross @entity1 removal from the middle ear, parotid gland, and superior cervical lymph nodes is followed by postoperative full-therapy irradiation. This combined approach has been used in 30 @entity0 with @entity1 involving the external auditory canal and temporal bone. The preoperative evaluation and surgical technique, including the intraoperative decision-making process, is described. Twenty-four @entity0 had @entity3 of the external auditory canal, and two @entity0 had @entity4 . There was one @entity0 each with @entity7 , @entity10 , high grade @entity9 , and a @entity8 . This group of @entity0 was broken down into three groups based on the extent of disease as determined at surgery. Overall control of disease, both locally and distant, for the 30 @entity0 was 66%. There were 12 @entity0 with disease limited to the ear canal. These @entity0 had a 91% survival of this disease process. Seven @entity0 were determined to have limited extension beyond the ear canal. These were treated with combined therapy with an overall control of disease of 72%. Eleven @entity0 had @entity2 outside of middle ear into the carotid jugular spine, stylomastoid foramen, and skull base, with a survival rate of 45%. It is concluded that a step-wise removal of all gross @entity1 , as opposed to an en bloc dissection of the temporal bone and skull base, followed by full-therapy irradiation gives equally as good, or even better, long-term survival for this @entity6 .

title: XXXX of the external ear canal and temporal bone: surgical techniques and results.

answer: @entity1


abstract: @entity7 ( @entity7 ) account for a significant proportion of @entity0 and childhood mortality and devastating @entity1 . Determining the specific diagnosis of @entity7 is challenging due to thousands of unique or rare genetic variants that result in overlapping phenotypes. We present four unique childhood @entity2 cases characterized by relatively mild @entity3 , slowly progressing course, mildly elevated @entity5 phosphokinase (CPK), and @entity6 . We also present two additional cases characterized by severe prenatal/neonatal @entity2 . Prior extensive genetic testing and histology of these cases did not reveal the genetic etiology of disease. Here, we applied whole exome sequencing (WES) and bioinformatics to identify likely causal pathogenic variants in each pedigree. In two cases, we identified novel pathogenic variants in @entity9 . In a third case, we identified novel likely pathogenic variants in @entity11 and @entity9 . We identified a novel splice variant in EMD in a fourth case. Finally, we classify two cases as @entity4 channelopathies with identification of novel pathogenic variants in @entity8 and @entity10 . These are the first cases of @entity2 reported to be caused by variants in @entity11 and @entity10 . Our results demonstrate the utility and genetic diagnostic value of WES in the broad class of @entity7 phenotypes.

title: Novel pathogenic variants and genes for XXXX identified by whole exome sequencing.

answer: @entity2


abstract: BACKGROUND: The Quality of life @entity1 (QoL. @entity2 ) Questionnaire specifically measures quality of life in @entity0 with @entity1 . AIM: To adapt a version translated into Spanish of the questionnaire and assess its validity in Chilean @entity0 . MATERIAL AND METHODS: The QoL. @entity2 was adapted to the Chilean population through the back-translation method and then administered to 32 adult @entity0 with a @entity1 and 31 subjects without the disease, both groups with similar socioeconomic status. To confirm the diagnosis, the International Neuropsychiatric Interview (MINI), Young (YMRS) and Hamilton (HAM-D) scales were applied. Quality of life was assessed using the SF-36v.2 survey. We determined internal consistency, reliability, convergent validity, the cut-off point, and the sensibility and specificity of the scale. RESULTS: The Chilean version of the Questionnaire [QoL. @entity2 -CL] had a high reliability (a = 0.95) and a high validity in reference to external criteria (correlation coefficients with SF-36 ranging from 0.453 and 0.819; p < 0.01). A cut-off point of 170, with sensitivity of 87.9% and specificity of 80% was determined. CONCLUSIONS: QoL. @entity2 -CL has adequate psychometric properties, as well as an adequate sensitivity and specificity to distinguish between negative and positive perceptions of life quality in Chilean @entity0 with @entity1 .

title: [Assessment of a version adapted and translated into Spanish of the Quality of Life XXXX Questionnaire].

answer: @entity1


abstract: BACKGROUND: To scan a virus (TOSV) belongs to the Phlebovirus genus within the Bunyaviridae family. TOSV is an arbovirus transmitted by sandflies. In Mediterranean countries, TOSV is one of the major viral pathogens involved in @entity3 and @entity2 . OBJECTIVES: Development and assessment of a new sensitive and specific real-time RT-PCR assay for TOSV diagnosis. STUDY DESIGN: TOSV-specific primers and probe targeting the S-segment of the genome were designed, based on recent TOSV sequences available in public databases. Sensitivity was assessed using 10-fold serial dilutions of a RNA transcript and serial dilutions of TOSV strains isolated from infected @entity0 beings. Specificity was determined by testing RNA extracts from closely related Phleboviruses. The assay was then used for @entity1 diagnosis in 971 clinical samples and for TOSV detection in 2000 sandflies. RESULTS: The real-time RT-PCR assay exhibited a sensitivity of under 257 copies per reaction for the RNA transcripts and 0.0056 and 0.014 TCID50 of Italian and Spanish TOSV genotypes per reaction, respectively. No other close Phleboviruses were detected. TOSV was identified in 17 clinical samples and in 3 sandflies. CONCLUSIONS: The assay described is a rapid, robust and reliable real-time RT-PCR test for accurate diagnosis of @entity0 @entity1 as well as for the surveillance of TOSV in vector populations.

title: A rapid and specific real time RT-PCR assay for diagnosis of Toscana XXXX .

answer: @entity1


abstract: BACKGROUND: The aim of the study was to assess the effect of a single intravenous dose of @entity3 administered before surgery in @entity0 undergoing total cementless hip arthroplasty on: intra-, post-, and perioperative blood lost, the number of @entity0 requiring transfusion, the incidence of @entity4 Material and methods. The study enrolled 124 @entity0 , who were randomly divided into two groups. The experimental group (61 @entity0 ) received an intravenous dose of 15 mg/kg of @entity3 20 minutes before the skin incision, while the control group (63 @entity0 ) did not receive this drug. We analysed intraoperative @entity2 (volume of blood in the aspirator), @entity1 (volume of blood drained), total perioperative @entity2 , and the number of @entity0 requiring transfusion as well as the number of @entity4 in both groups. RESULTS: In the experimental group, mean intraoperative @entity2 was significantly lower at 216 ml compared to 408.5 ml in the control group (p=0.00421). Postoperative @entity2 on the first postoperative day was also lower in the experimental group (246.3 ml) as compared with the control group (358 ml, p=0.000097). Estimated perioperative @entity2 in the experimental group was lower as well, reaching 779 ml, vs. 1315.5 ml in the control group (p=0.00567). The percentage of @entity0 requiring transfusion in the experimental group (3.27%) was significantly lower than in the control group (22.22%) (p=0.00166). The use of @entity3 did not influence the number of @entity4 (p=0.3075). CONCLUSIONS: 1. The administration of 15 mg/kg of @entity3 20 minutes before surgery decreases the need for postoperative transfusion of allogeneic blood due to a significant reduction in intra-, post-, and perioperative @entity2 . 2. Seeing that this method does not increase the number of @entity4 and is simple and inexpensive, it should be considered worthy of recommendation in total cementless hip arthroplasty.

title: Effect of Single Preoperative Dose of XXXX on @entity2 and Transfusion in Hip Arthroplasty.

answer: @entity3


abstract: BACKGROUND: The aim of the study was to assess the effect of a single intravenous dose of @entity3 administered before surgery in @entity0 undergoing total cementless hip arthroplasty on: intra-, post-, and perioperative blood lost, the number of @entity0 requiring transfusion, the incidence of @entity4 Material and methods. The study enrolled 124 @entity0 , who were randomly divided into two groups. The experimental group (61 @entity0 ) received an intravenous dose of 15 mg/kg of @entity3 20 minutes before the skin incision, while the control group (63 @entity0 ) did not receive this drug. We analysed intraoperative @entity2 (volume of blood in the aspirator), @entity1 (volume of blood drained), total perioperative @entity2 , and the number of @entity0 requiring transfusion as well as the number of @entity4 in both groups. RESULTS: In the experimental group, mean intraoperative @entity2 was significantly lower at 216 ml compared to 408.5 ml in the control group (p=0.00421). Postoperative @entity2 on the first postoperative day was also lower in the experimental group (246.3 ml) as compared with the control group (358 ml, p=0.000097). Estimated perioperative @entity2 in the experimental group was lower as well, reaching 779 ml, vs. 1315.5 ml in the control group (p=0.00567). The percentage of @entity0 requiring transfusion in the experimental group (3.27%) was significantly lower than in the control group (22.22%) (p=0.00166). The use of @entity3 did not influence the number of @entity4 (p=0.3075). CONCLUSIONS: 1. The administration of 15 mg/kg of @entity3 20 minutes before surgery decreases the need for postoperative transfusion of allogeneic blood due to a significant reduction in intra-, post-, and perioperative @entity2 . 2. Seeing that this method does not increase the number of @entity4 and is simple and inexpensive, it should be considered worthy of recommendation in total cementless hip arthroplasty.

title: Effect of Single Preoperative Dose of @entity3 on XXXX and Transfusion in Hip Arthroplasty.

answer: @entity2


abstract: OBJECTIVES: To identify and synthesise the best available evidence on the accuracy of the currently available tools for predicting @entity1 risk. METHODS: We systematically searched PubMed MEDLINE, Embase and Cochrane databases to 2014. Two reviewers independently selected articles, collected data from studies, and carried out a hand search of the references of the included studies. The Quality Assessment Tool for Diagnostic Accuracy Studies (QUADAS) checklist was used, and the primary outcome was the area under the curve (AUC) and 95% CIs, obtained from receiver operating characteristic (ROC) analyses. We excluded tools if they had not been externally validated or were designed for specific disease populations. Random effects meta-analyses were performed with the selected tools. RESULTS: Forty-five studies met inclusion criteria, corresponding to 13 different tools. Only three tools had been tested more than once in a population-based setting: FRAX (26 studies in 9 countries), GARVAN (6 studies in 3 countries) and QFracture (3 studies in the UK, 1 also including Irish @entity0 ). Twenty studies with these three tools were included in a total of 17 meta-analyses (for hip or major @entity2 ; @entity0 or @entity0 ; with or without bone mineral density). CONCLUSIONS: Most of the 13 tools are feasible in clinical practice. FRAX has the largest number of externally validated and independent studies. The overall accuracy of the different tools is satisfactory (>0.70), with QFracture reaching 0.89 (95% CI 0.88 to 0.89). Significant methodological limitations were observed in many studies, suggesting caution when comparing tools based solely on the AUC.

title: The accuracy of XXXX risk prediction tools: a systematic review and meta-analysis.

answer: @entity2


abstract: RATIONALE: @entity3 can raise problems to diagnostic imaging. The radiologist must choose the most appropriate examination that delivers the most important diagnostic information because the differences between a lithiasic obstruction and a tumoral one are vital. This information helps the surgeon speed up the process of decision-making, because the treatment may be very different in relation to the nature of the obstruction. OBJECTIVE: This study tries to demonstrate the diagnostic accuracy of computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) in detecting the obstacle in the common bile duct (CBD) and the possibility of establishing the lithiasic nature of the obstruction. METHODS AND RESULTS: A retrospective analysis was analyzed during an interval of 18 months that included @entity1 @entity0 admitted in the General Surgery Department of "Coltea" Clinical Hospital. They were examined by CT scanning and by MRCP, being suspected of @entity2 . 63 @entity0 were included in the study, 34 females and 29 males. 33 CT scans and 30 MRCP exams were performed. DISCUSSION: CT scan is useful in detecting residual or iterative @entity2 in @entity0 after cholecystectomy, contrast enhanced CT (CECT), being able to differentiate between lithiasic and non-lithiasic obstruction. MRCP delivers important anatomic details of the biliary tree; it is superior to CT in diagnosing the @entity4 ; MRCP tends to replace endoscopic retrograde cholangiopancreatography (ERCP) - the diagnostic "gold standard" reducing the number of unnecessary invasive diagnostic procedures. ABBREVIATIONS: CT = computed tomography, CECT = contrast enhanced computed tomography, ERCP = endoscopic retrograde cholangiopancreatography, MRCP = magnetic resonance cholangiopancreatography, CBD = common bile duct.

title: CT vs. MRCP in @entity2 XXXX .

answer: @entity1


abstract: RATIONALE: @entity3 can raise problems to diagnostic imaging. The radiologist must choose the most appropriate examination that delivers the most important diagnostic information because the differences between a lithiasic obstruction and a tumoral one are vital. This information helps the surgeon speed up the process of decision-making, because the treatment may be very different in relation to the nature of the obstruction. OBJECTIVE: This study tries to demonstrate the diagnostic accuracy of computed tomography (CT) and magnetic resonance cholangiopancreatography (MRCP) in detecting the obstacle in the common bile duct (CBD) and the possibility of establishing the lithiasic nature of the obstruction. METHODS AND RESULTS: A retrospective analysis was analyzed during an interval of 18 months that included @entity1 @entity0 admitted in the General Surgery Department of "Coltea" Clinical Hospital. They were examined by CT scanning and by MRCP, being suspected of @entity2 . 63 @entity0 were included in the study, 34 females and 29 males. 33 CT scans and 30 MRCP exams were performed. DISCUSSION: CT scan is useful in detecting residual or iterative @entity2 in @entity0 after cholecystectomy, contrast enhanced CT (CECT), being able to differentiate between lithiasic and non-lithiasic obstruction. MRCP delivers important anatomic details of the biliary tree; it is superior to CT in diagnosing the @entity4 ; MRCP tends to replace endoscopic retrograde cholangiopancreatography (ERCP) - the diagnostic "gold standard" reducing the number of unnecessary invasive diagnostic procedures. ABBREVIATIONS: CT = computed tomography, CECT = contrast enhanced computed tomography, ERCP = endoscopic retrograde cholangiopancreatography, MRCP = magnetic resonance cholangiopancreatography, CBD = common bile duct.

title: CT vs. MRCP in XXXX @entity1 .

answer: @entity2


abstract: BACKGROUND: Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)(+) polarized T-cell subsets in @entity0 versus adults with @entity4 ( @entity4 ) is critical for directing new treatments toward @entity0 . OBJECTIVE: We sought to compare activation markers and frequencies of skin-homing (CLA(+)) versus systemic (CLA(-)) "polar" @entity2 and @entity3 T-cell subsets in @entity0 with early pediatric @entity4 , adults with @entity4 , and control subjects. METHODS: Flow cytometry was used to measure @entity9 /inducible costimulator/HLA-DR frequency in memory cell subsets, as well as IFN-y, @entity6 , @entity8 , @entity7 , and @entity10 cytokines, defining @entity12 , TH2/ @entity11 , TH9/TC9, TH17/TC17, and TH22/TC22 populations in @entity2 and @entity3 cells, respectively. We compared peripheral blood from 19 @entity0 less than 5 years old and 42 adults with well-characterized moderate-to-severe @entity4 , as well as age-matched control subjects (17 @entity0 and 25 adults). RESULTS: Selective inducible costimulator activation (P < .001) was seen in @entity0 . CLA(+) TH2 T cells were markedly expanded in both @entity0 and adults with @entity4 compared with those in control subjects, but decreases in CLA(+) @entity5 T-cell numbers were greater in @entity0 with @entity4 (17% vs 7.4%, P = .007). Unlike in adults, no imbalances were detected in CLA(-) T cells from pediatric @entity0 with @entity4 nor were there altered frequencies of TH22 T cells within the CLA(+) or CLA(-) compartments. Adults with @entity4 had increased frequencies of @entity10 -producing @entity2 and @entity3 T cells within the skin-homing population, compared with controls (9.5% vs 4.5% and 8.6% vs 2.4%, respectively; P < .001), as well as increased HLA-DR activation (P < .01). CONCLUSIONS: These data suggest that TH2 activation within skin-homing T cells might drive @entity4 in @entity0 and that reduced counterregulation by @entity5 T cells might contribute to excess TH2 activation. TH22 "spreading" of @entity4 is not seen in young @entity0 and might be influenced by immune development, disease chronicity, or recurrent @entity1 .

title: Early pediatric XXXX shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/ @entity5 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets.

answer: @entity4


abstract: BACKGROUND: Identifying differences and similarities between cutaneous lymphocyte antigen (CLA)(+) polarized T-cell subsets in @entity0 versus adults with @entity4 ( @entity4 ) is critical for directing new treatments toward @entity0 . OBJECTIVE: We sought to compare activation markers and frequencies of skin-homing (CLA(+)) versus systemic (CLA(-)) "polar" @entity2 and @entity3 T-cell subsets in @entity0 with early pediatric @entity4 , adults with @entity4 , and control subjects. METHODS: Flow cytometry was used to measure @entity9 /inducible costimulator/HLA-DR frequency in memory cell subsets, as well as IFN-y, @entity6 , @entity8 , @entity7 , and @entity10 cytokines, defining @entity12 , TH2/ @entity11 , TH9/TC9, TH17/TC17, and TH22/TC22 populations in @entity2 and @entity3 cells, respectively. We compared peripheral blood from 19 @entity0 less than 5 years old and 42 adults with well-characterized moderate-to-severe @entity4 , as well as age-matched control subjects (17 @entity0 and 25 adults). RESULTS: Selective inducible costimulator activation (P < .001) was seen in @entity0 . CLA(+) TH2 T cells were markedly expanded in both @entity0 and adults with @entity4 compared with those in control subjects, but decreases in CLA(+) @entity5 T-cell numbers were greater in @entity0 with @entity4 (17% vs 7.4%, P = .007). Unlike in adults, no imbalances were detected in CLA(-) T cells from pediatric @entity0 with @entity4 nor were there altered frequencies of TH22 T cells within the CLA(+) or CLA(-) compartments. Adults with @entity4 had increased frequencies of @entity10 -producing @entity2 and @entity3 T cells within the skin-homing population, compared with controls (9.5% vs 4.5% and 8.6% vs 2.4%, respectively; P < .001), as well as increased HLA-DR activation (P < .01). CONCLUSIONS: These data suggest that TH2 activation within skin-homing T cells might drive @entity4 in @entity0 and that reduced counterregulation by @entity5 T cells might contribute to excess TH2 activation. TH22 "spreading" of @entity4 is not seen in young @entity0 and might be influenced by immune development, disease chronicity, or recurrent @entity1 .

title: Early pediatric @entity4 shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/ XXXX cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets.

answer: @entity5


abstract: OBJECTIVES: In paediatric cardiac surgery, reoperations remain challenging since the injury and the formation of dense adhesions before reoperations can be life-threatening to the heart, bypass conduits or great vessels. To prevent the formation of dense adhesions, a variety of different types of pericardial membrane substitute have been employed. However, due to peel formation, @entity4 and infection, the routine application of these pericardial membrane substitute has not been achieved clinically. A novel bioabsorbable membrane has been developed from @entity6 ( @entity5 ) to overcome these drawbacks. The purpose of this study was to assess the biosafety and the effectiveness of @entity5 membrane as a new bioabsorbable pericardial membrane substitute after pericardium replacement in a @entity3 model. METHODS: A total of 33 @entity3 underwent abrasion on the surface of the heart through right thoracotomy and were divided into a @entity5 membrane group (n = 17) and a control group (n = 16). Biosafety was assessed by comparing pre- and postoperative @entity1 and C-reactive protein levels. Subsequently, at 4 and 12 weeks postoperatively, the degree of reabsorption of the membrane and the intensity of adhesions were macroscopically assessed, followed by a microscopic evaluation for histological changes. Samples of the regenerated fibrous membranes that were harvested 12 weeks after implantation were used to perform immunostaining for cytokeratin and @entity0 bone marrow endothelial cell-1 (HBME-1). RESULTS: The @entity5 membrane group exhibited a little inflammatory response (P > 0.05) and @entity1 (P > 0.05). The @entity5 membrane was mostly absorbed by 12 weeks with the replacement of loosely adherent tissue. Moderate adhesions were found between the pericardial membrane substitute and the epicardium at the 4-week postoperative inspection. After 12 weeks postoperatively, the adhesions were found to have resolved completely. The composite score, which combined the histological findings of @entity2 and the tightness of adhesions, was graded on a scale of 0 to 3. Significant differences between the @entity5 and control groups were detected at 4 weeks (1.2    0.4, 2.1    0.6; P = 0.007, respectively) and 12 weeks (0.5    0.5, 2.5    0.7; P = 0.001, respectively). Twelve weeks after the replacement of the pericardium with the @entity5 membrane, as shown by the cells positively immunostained for cytokeratin and HBME-1, the regenerated membrane consisted of a bilayer structure mimicking the native pericardium. CONCLUSIONS: To prevent the formation of adhesions after cardiac surgery, the bioabsorbable @entity5 membrane might serve as a promising substitute for the pericardium, which proved to be safe and efficacious in our study.

title: A novel bioabsorbable pericardial membrane substitute to reduce postoperative pericardial adhesions in a XXXX model.

answer: @entity3


abstract: BACKGROUND: New targeted @entity1 therapies such as @entity2 inhibitors have shown high and promising clinical benefit but have cutaneous side-effects, including photosensitivity, which is triggered in the UVA radiation spectrum. However, visible spectrum implication has not yet been investigated. We conducted a study to determine whether visible light also contributes to the @entity5 action spectrum of @entity3 . The secondary end points were to determine the time to complete regression of the @entity5 post- @entity3 discontinuation and whether there was a significant difference between the UVA radiation immediate reactivity cut-offs, in @entity0 treated with @entity3 vs. those treated with @entity4 . METHOD: This prospective, observational study included @entity0 with @entity2 mutant metastatic @entity1 : 34 @entity0 treated with @entity3 and 9 with @entity4 . RESULTS: The visible-light phototest results in @entity0 treated with @entity3 were all negative before and after 2 months of treatment. The UVA radiation phototests conducted 1 or 2 weeks post- @entity3 discontinuation in 4 @entity0 showed a normalised UVA-radiation reactivity cut-off. UVA radiation phototests after 2 months of treatment were conducted for all @entity0 . The UVA radiation reactivity cut-off had been lowered for 30 @entity0 (88%) on @entity3 and 3 @entity0 (33%) on @entity4 . The median UVA radiation reactivity cut-off was 12  J/cm(2) for the @entity0 on @entity3 and 20  J/cm(2) for the @entity0 on @entity4 . CONCLUSION: @entity2 inhibitor @entity5 is exclusively triggered by UVA radiation and resolves rapidly post-treatment discontinuation. A significant difference between the UVA immediate reactivity cut-offs, @entity3 vs. @entity4 , explains the difference in the clinical photosensitivity rates reported in the clinical trials.

title: XXXX of @entity2 inhibitors: Exclusively due to UVA radiation and rapidly regressive.

answer: @entity5


abstract: BACKGROUND: New targeted @entity1 therapies such as @entity2 inhibitors have shown high and promising clinical benefit but have cutaneous side-effects, including photosensitivity, which is triggered in the UVA radiation spectrum. However, visible spectrum implication has not yet been investigated. We conducted a study to determine whether visible light also contributes to the @entity5 action spectrum of @entity3 . The secondary end points were to determine the time to complete regression of the @entity5 post- @entity3 discontinuation and whether there was a significant difference between the UVA radiation immediate reactivity cut-offs, in @entity0 treated with @entity3 vs. those treated with @entity4 . METHOD: This prospective, observational study included @entity0 with @entity2 mutant metastatic @entity1 : 34 @entity0 treated with @entity3 and 9 with @entity4 . RESULTS: The visible-light phototest results in @entity0 treated with @entity3 were all negative before and after 2 months of treatment. The UVA radiation phototests conducted 1 or 2 weeks post- @entity3 discontinuation in 4 @entity0 showed a normalised UVA-radiation reactivity cut-off. UVA radiation phototests after 2 months of treatment were conducted for all @entity0 . The UVA radiation reactivity cut-off had been lowered for 30 @entity0 (88%) on @entity3 and 3 @entity0 (33%) on @entity4 . The median UVA radiation reactivity cut-off was 12  J/cm(2) for the @entity0 on @entity3 and 20  J/cm(2) for the @entity0 on @entity4 . CONCLUSION: @entity2 inhibitor @entity5 is exclusively triggered by UVA radiation and resolves rapidly post-treatment discontinuation. A significant difference between the UVA immediate reactivity cut-offs, @entity3 vs. @entity4 , explains the difference in the clinical photosensitivity rates reported in the clinical trials.

title: @entity5 of XXXX inhibitors: Exclusively due to UVA radiation and rapidly regressive.

answer: @entity2


abstract: BACKGROUND: While cooled radiofrequency ablation (C-RFA) appears to be a promising technology for joint denervation, outcomes of this technique for the treatment of @entity3 have not been described. We report clinical outcomes in a case series of @entity0 treated with C-RFA for @entity3 . METHODS: Consecutive @entity0 aged 18-60 years diagnosed with @entity3 , confirmed by >= 75% symptom relief with at least one set of diagnostic medial branch nerve blocks, who underwent C-RFA between January 2007 and December 2013 in an urban @entity1 center were included. The respective proportions of @entity0 who reported >= 50% improvement in @entity1 and in function were calculated. Change in median NRS score, daily @entity2 equivalent consumption (DME), and medication quantification scale III (MQS III) score were measured. RESULTS: Twelve @entity0 underwent C-RFA; three were lost to follow-up. The median and 25%-75% interquartile range (IQR) for age was 44 years (35, 54). The median duration of follow-up was 34 months, IQR (21, 55). The percentage and 95% confidence interval (CI) of @entity0 who reported >= 50% improvement in @entity1 was 33% CI (12%, 64%) and in function was 78%, CI (41%, 96%). There was no significant change in DME or MSQ III score. Approximately 50% of @entity0 sought additional healthcare by long-term follow-up. No complications were reported. CONCLUSIONS: This case series suggests that C-RFA may improve function and to a @entity1 at long-term follow-up. A randomized, controlled trial is warranted.

title: A Novel Modality for Facet Joint Denervation: Cooled Radiofrequency Ablation for XXXX . A Case Series.

answer: @entity3


abstract: BACKGROUND: Inflammation-related parameters based on blood cells, including white blood cell (WBC) count, neutrophil-lymphocyte ratio, platelet count, and red cell distribution width (RDW), have been shown to be associated with prognosis in many @entity1 . However, no previous study evaluated these inflammation-associated markers simultaneously in upper tract @entity2 (UTUC). METHODS: A total of 195 @entity0 with UTUC who received radical nephroureterectomy between 2005 and 2010 were included retrospectively as the derivation cohort to investigate the impact of inflammation markers on @entity3 ( @entity3 ) and @entity1 -specific survival (CSS). In turn, another independent set of 225 @entity0 were used for validation. Finally, we performed survival analysis in the combined cohort consisting of 420 UTUC @entity0 . RESULTS: The predictive value of RDW and WBC count on outcome was replicable in different cohorts. Multivariate analysis showed high RDW was independently associated with poor @entity3 (P < 0.001), and WBC count was a significant prognosticator for both @entity3 and CSS (both P < 0.001). In subgroup analysis, we found the prognostic significance of RDW for @entity3 was limited in organ-confined disease ( <=pT2 without pN+). More importantly, a clear survival difference can be demonstrated by combining RDW and WBC count with other known prognostic factors in the risk stratification model. CONCLUSIONS: RDW and WBC count have the advantage of their common accessibility and are useful markers to predict outcome of UTUC in the preoperative setting. RDW and WBC count could provide additional prognostic value and help physicians identify @entity0 at high risk for mortality and formulate individualized treatment strategy.

title: The Prognostic Significance of Inflammation-Associated Blood Cell Markers in @entity0 with Upper Tract XXXX .

answer: @entity2


abstract: BACKGROUND: Inflammation-related parameters based on blood cells, including white blood cell (WBC) count, neutrophil-lymphocyte ratio, platelet count, and red cell distribution width (RDW), have been shown to be associated with prognosis in many @entity1 . However, no previous study evaluated these inflammation-associated markers simultaneously in upper tract @entity2 (UTUC). METHODS: A total of 195 @entity0 with UTUC who received radical nephroureterectomy between 2005 and 2010 were included retrospectively as the derivation cohort to investigate the impact of inflammation markers on @entity3 ( @entity3 ) and @entity1 -specific survival (CSS). In turn, another independent set of 225 @entity0 were used for validation. Finally, we performed survival analysis in the combined cohort consisting of 420 UTUC @entity0 . RESULTS: The predictive value of RDW and WBC count on outcome was replicable in different cohorts. Multivariate analysis showed high RDW was independently associated with poor @entity3 (P < 0.001), and WBC count was a significant prognosticator for both @entity3 and CSS (both P < 0.001). In subgroup analysis, we found the prognostic significance of RDW for @entity3 was limited in organ-confined disease ( <=pT2 without pN+). More importantly, a clear survival difference can be demonstrated by combining RDW and WBC count with other known prognostic factors in the risk stratification model. CONCLUSIONS: RDW and WBC count have the advantage of their common accessibility and are useful markers to predict outcome of UTUC in the preoperative setting. RDW and WBC count could provide additional prognostic value and help physicians identify @entity0 at high risk for mortality and formulate individualized treatment strategy.

title: The Prognostic Significance of Inflammation-Associated Blood Cell Markers in XXXX with Upper Tract @entity2 .

answer: @entity0


abstract: OBJECTIVE: Elderly with several pathologies are usually treated with many drugs, and are exposed to a majored risk of drug-induced adverse effects. A network of local nursing homes (EHPAD) in the south Seine-Saint-Denis area (France) created a geriatric drug guidelines to improve the quality of the drugs prescriptions. This study assesses the conformity of prescriptions in elderly @entity0 prior and after the distribution of the booklet. METHODS: This before and after design study focused on the drug prescriptions for @entity0 in eight EHPAD followed for two randomly given days in 2012 (n = 503) and 2013 (n = 334). The geriatric drug guidelines included a list of medicines suitable for the elderly (conformity list) and recommendations for prescription and monitoring. Data collection was conducted from medical records and interviews with coordinators doctors and nursing staff in nursing homes. A 6 items-quality score was calculated, ranging from 0 (lowest quality) to 6 (highest quality). RESULTS: Median age, weight and @entity1 level were respectively 88 years, 61.0 kg, and 74.9  mol/L (prior) and 88 years, 59.6 kg, and 77.0  mol/L (after). Median times of latest serum @entity1 dosage were 112 days (prior) and 108 days (after). The median number of prescribed drugs was 8 per resident during the two period of study. The conformity rate of prescription was better prior the distribution of the guidelines, respectively 87.5% and 80.0% ( @entity2     ). The average formal quality score was better after the distribution of the booklet increasing form 4.23 to 4.40 points ( @entity2      ). For high risk inducing drugs, monitoring was prescribed in 34.2% (prior) and 32.4% (after). CONCLUSIONS: This study shows that the drug geriatric guidelines does not improve prescription conformity and monitoring for high risk drugs, but it does significantly improve the median formal quality score.

title: [Impact of Geriatric Drug Guidelines on the Quality Requirement of Elderly XXXX ].

answer: @entity0


abstract: Electrical stimulation of the trigeminal nerve evokes a ;short latency depolarization' ( @entity1 ) in the first order sensory neurones of the mesencephalic nucleus (MSN) of the Vth nerve in the @entity0 . A series of experiments suggesting ;electrotonic coupling' as the mechanism for this @entity1 is provided.1. Electrical activity of MSN neurones was recorded intracellularly as action potentials were conducted from the periphery (somatopetally) to the masticatory nucleus. Typical sequential invasion of the initial segment and somatic region (IS-S) of the neurones was seen. The somatopetal activation of MSN neurones was characterized by the brevity, short refractoriness, high safety factor (IS-S), and short after-hyperpolarization of the spike potential.2. In twenty-three (10.5%) of the penetrated neurones, stimulation at levels subthreshold for somatopetal activation uncovered a @entity1 with a mean latency of 180 musec.3. The SLDs were found to be all-or-none in nature, and to have constant amplitude and latency for a given cell, plus a short half decay time.4. Hyperpolarization of a MSN neurone through the recording electrode produced a blockage of the IS-S spike and revealed M-spikes and SLDs which could be clearly separated, in every instance, as distinct all-or-none components. The amplitude of the @entity1 was found to be insensitive to the level of membrane potential within the ranges tested.5. In fifteen neurones the @entity1 generated action potentials which were conducted somatofugally as shown by their collision with somatopetally conducted action potentials in the same cell. The lack of collision between the @entity1 and somatopetal spikes demonstrated the independent origin of these two potentials.6. The independence of the @entity1 from the somatopetal invasion of the cell was also demonstrated by collision of a somatofugal action potential following direct stimulation through the recording micro-electrode and a somatopetal spike following trigeminal stimulation.7. Two possible mechanisms are considered for the genesis of the @entity1 : chemical synaptic transmission and electrotonic coupling between neighbouring cells. The conclusion is drawn that SLDs must be generated by the latter mechanism.

title: Electrotonic coupling between neurones in the XXXX mesencephalic nucleus.

answer: @entity0


abstract: OBJECTIVES: The interferon (IFN) signature ( @entity5 ) in @entity0 with @entity3 ( @entity3 ) includes over 100 genes induced by type I IFN pathway activation. We developed a method to quantify the @entity5 using three genes-the @entity5 ( @entity5 )-and characterised the clinical characteristics of @entity0 with @entity3 with different @entity5 status from multiple clinical trials. METHODS: Blood microarray expression data from a training cohort of @entity0 with @entity3 confirmed the presence of the @entity5 and identified surrogate genes. We assayed these genes in a quantitative PCR (qPCR) assay, yielding an @entity5 from the @entity5 . The association of @entity5 status with clinical disease characteristics was assessed in @entity0 with extrarenal lupus and @entity4 from four clinical trials. RESULTS: Three genes, @entity8 , EPSTI and @entity7 , correlated well with the @entity5 (p>0.96), and composed the @entity5 qPCR assay. Using the 95th centile for healthy control data, @entity0 with @entity3 from different studies were classified into two @entity5 subsets- @entity5 -Low and @entity5 -High-that are longitudinally stable over 36   weeks. Significant associations were identified between @entity5 -High status and higher titres of anti-dsDNA antibodies, presence of anti extractable nuclear antigen autoantibodies, elevated serum @entity6 of the @entity1 necrosis factor family ( @entity6 ) levels, and hypocomplementaemia. However, measures of overall clinical disease activity were similar for @entity5 -High and @entity5 -Low groups. CONCLUSIONS: The @entity5 is an @entity5 biomarker that divides @entity0 with @entity3 into two subpopulations- @entity5 -High and @entity5 -Low-with differing serological manifestations. The @entity5 does not distinguish between high and low disease activity, but may have utility in identifying @entity0 more likely to respond to treatment(s) targeting @entity2 . CLINICALTRIALSGOV REGISTRATION NUMBER: NCT00962832.

title: Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of @entity0 with XXXX .

answer: @entity3


abstract: OBJECTIVES: The interferon (IFN) signature ( @entity5 ) in @entity0 with @entity3 ( @entity3 ) includes over 100 genes induced by type I IFN pathway activation. We developed a method to quantify the @entity5 using three genes-the @entity5 ( @entity5 )-and characterised the clinical characteristics of @entity0 with @entity3 with different @entity5 status from multiple clinical trials. METHODS: Blood microarray expression data from a training cohort of @entity0 with @entity3 confirmed the presence of the @entity5 and identified surrogate genes. We assayed these genes in a quantitative PCR (qPCR) assay, yielding an @entity5 from the @entity5 . The association of @entity5 status with clinical disease characteristics was assessed in @entity0 with extrarenal lupus and @entity4 from four clinical trials. RESULTS: Three genes, @entity8 , EPSTI and @entity7 , correlated well with the @entity5 (p>0.96), and composed the @entity5 qPCR assay. Using the 95th centile for healthy control data, @entity0 with @entity3 from different studies were classified into two @entity5 subsets- @entity5 -Low and @entity5 -High-that are longitudinally stable over 36   weeks. Significant associations were identified between @entity5 -High status and higher titres of anti-dsDNA antibodies, presence of anti extractable nuclear antigen autoantibodies, elevated serum @entity6 of the @entity1 necrosis factor family ( @entity6 ) levels, and hypocomplementaemia. However, measures of overall clinical disease activity were similar for @entity5 -High and @entity5 -Low groups. CONCLUSIONS: The @entity5 is an @entity5 biomarker that divides @entity0 with @entity3 into two subpopulations- @entity5 -High and @entity5 -Low-with differing serological manifestations. The @entity5 does not distinguish between high and low disease activity, but may have utility in identifying @entity0 more likely to respond to treatment(s) targeting @entity2 . CLINICALTRIALSGOV REGISTRATION NUMBER: NCT00962832.

title: Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of XXXX with @entity3 .

answer: @entity0


abstract: During the past years, magnetic resonance imaging (MRI) has been established as a reliable method for examination of the kidneys. Modern MRI systems enable to visualize renal masses with a high spatial resolution. This enables not only to differentiate between @entity2 but also to define the @entity1 stage with high accuracy. The impact of a precise preoperative staging has increased significantly due to stage adapted therapy approaches such as nephron sparing surgery or local ablative techniques (e.g. radiofrequency ablation). Tumor-related infiltration of the renal pelvis, infiltration of the perinephric fat or a @entity1 thrombus within the inferior caval vein has to be diagnosed with high accuracy to enable these stage adapted treatment regimens. This article introduces into clinically established "morphologic" MRI techniques for diagnosis and staging of @entity3 ( @entity3 ). Besides detection and staging of @entity2 , the recent development of molecularly targeted therapies in @entity0 with metastatic or non-operable @entity1 has led to novel diagnostic demands. To evaluate treatment efficiency, more information than just @entity1 morphology should be provided. Functional imaging techniques including dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), arterial spin labeling (ASL) and MR-spectroscopy are being investigated in preclinical and clinical trials. While some new techniques have shown promising results for a broad clinical application, others seem to be suited for dedicated questions only.

title: Current role and future perspective of MRI for diagnosis and characterization of XXXX .

answer: @entity3


abstract: OBJECTIVE: This study aimed to determine external and @entity1 , and satisfaction with nasal functioning and appearance, in @entity2 . STUDY DESIGN: A cross-sectional cohort study was conducted. METHODS: Eleven adult @entity0 with @entity2 were compared with 151 controls in terms of satisfaction with nasal functioning and appearance by means of the Nasal Appearance and Function Evaluation Questionnaire. In all @entity0 with @entity2 , external @entity1 were scored on standardized digital photographs of the nose as rated independently by three experienced physicians. @entity1 was determined by standardized nasal endoscopy. RESULTS: The @entity0 were relatively satisfied with the various esthetic nasal subunits. The most significant functional problems were snoring (P  =  0.001) and quality of phonation (P  =  0.003). The main external @entity1 were the dorsal hump (73%), external deviation ( <=55%), the bifid or bulbous nasal tip (55%), and @entity3 (55%). In 82% of the @entity0 , a septal deviation was found, often associated with spurs. CONCLUSION: Satisfaction with esthetics of the nose was fair, but these @entity0 suffer from the functional problems of snoring and impaired quality of phonation. A structured nasal ENT physical examination with nasal endoscopy might determine aspects requiring more attention during treatment. Septorhinoplasty can be performed at an adult age if there is a considerable esthetic wish of the @entity0 and/or nasal obstruction combined with septal deviation. Attention should be paid to dorsal hump reduction, correction of the deviated external osseous framework, septoplasty, and correction of the nasal tip shape. LEVEL OF EVIDENCE: 2b.

title: Nasal sequelae of XXXX .

answer: @entity2


abstract: PURPOSE: The goal of this study was to determine how frequently the conventionally defined "idiopathic" @entity8 are associated with subradiological cam deformities of the head-neck junction and whether a protective femoral osteochondroplasty may improve the outcome of their arthroscopic treatment. METHODS: All the non-arthritic or pre-arthritic @entity4 hips diagnosed as having a primary @entity2 were retrospectively evaluated. Coxometric data, clinical history and physical findings were reviewed to rule out any possible secondary lesion. The medical records of the selected cases were analyzed as for imaging features, surgical findings and post-arthroscopy outcome. RESULTS: Three cases out of 79 @entity2 were identified as "primary" on the basis of the preoperative assessment. All the three @entity0 were female in their fourth decade and showed a @entity1 consistent with undetected cam FAI (cartilage delamination in the anterolateral acetabular quadrant, minor pathology of the adjacent labrum with or without @entity6 , abrasion signs and @entity5 along the anterolateral head-neck junction). The first @entity0 received a simple chondrolabral treatment whose benefits deteriorated few months after surgery; the second @entity0 underwent @entity7 and is still pain-free; and the third @entity0 had a beneficial revision arthroscopy for femoral osteochondroplasty after prior unsuccessful chondrolabral surgery. CONCLUSIONS: If a @entity2 of the hip is associated with MR arthrographic and arthroscopic indirect signs of cam FAI, a subradiological @entity3 should be considered despite normal alpha angles. In such cases, a protective femoral osteochondroplasty may increase the success rate of the chondrolabral repair. LEVEL OF EVIDENCE: IV.

title: Subradiological cam deformity of the head-neck junction: an occult cause of @entity4 and XXXX .

answer: @entity1


abstract: PURPOSE: The goal of this study was to determine how frequently the conventionally defined "idiopathic" @entity8 are associated with subradiological cam deformities of the head-neck junction and whether a protective femoral osteochondroplasty may improve the outcome of their arthroscopic treatment. METHODS: All the non-arthritic or pre-arthritic @entity4 hips diagnosed as having a primary @entity2 were retrospectively evaluated. Coxometric data, clinical history and physical findings were reviewed to rule out any possible secondary lesion. The medical records of the selected cases were analyzed as for imaging features, surgical findings and post-arthroscopy outcome. RESULTS: Three cases out of 79 @entity2 were identified as "primary" on the basis of the preoperative assessment. All the three @entity0 were female in their fourth decade and showed a @entity1 consistent with undetected cam FAI (cartilage delamination in the anterolateral acetabular quadrant, minor pathology of the adjacent labrum with or without @entity6 , abrasion signs and @entity5 along the anterolateral head-neck junction). The first @entity0 received a simple chondrolabral treatment whose benefits deteriorated few months after surgery; the second @entity0 underwent @entity7 and is still pain-free; and the third @entity0 had a beneficial revision arthroscopy for femoral osteochondroplasty after prior unsuccessful chondrolabral surgery. CONCLUSIONS: If a @entity2 of the hip is associated with MR arthrographic and arthroscopic indirect signs of cam FAI, a subradiological @entity3 should be considered despite normal alpha angles. In such cases, a protective femoral osteochondroplasty may increase the success rate of the chondrolabral repair. LEVEL OF EVIDENCE: IV.

title: Subradiological cam deformity of the head-neck junction: an occult cause of XXXX and @entity1 .

answer: @entity4


abstract: OBJECTIVE: Pressure Ulcers   (PUs) often is an indication of quality of nursing care as it remains as severe manifestation of the integrity of impaired skin. Our study designed to evaluate the effectiveness of hydrocolloid dressings and @entity2 dressings in healing of PU. @entity0 AND METHODS: The study was done at Chinese hospital between Feb 2014-November 2014. 72 study group @entity0 and 25 control group @entity0 were included in the study. The study group @entity0 were divided into Group A with 24 @entity0 received only ordinary hydrocolloid dressings, Group B with 24 @entity0 who @entity2 containing hydrocolloid dressings and Group C with 24 @entity0 received both @entity4 and @entity2 dressings. Dressings were applied for 4 weeks. The dressings were changed every 10 days and @entity1 such as pH of the skin, hydration are measured by capacitive method. RESULTS: Among 72 study population 48 (66.7%) were male and 24 (33.3%) were females. Group A with 18 (75%) males and 6 (25%) females, group B with 20 (83.3%) males and 4 (16.7%) females, and group C with 10 (41.7%) males and 14 (58.3%) females. 25 Control group @entity0 with 8 (32%) males and 16 (68%) females. Erythema seen in 4/24 (16.67%) group A @entity0 , group B and C @entity0 had 1/24 (4.17%) @entity3 . In control group @entity0 6/25(24%) developed @entity3 . CONCLUSIONS: In our study, we evaluated the effectiveness of the hydrocolloid dressings and @entity2 containing dressings in which @entity2 containing dressings showed effective prevention and water holding capacity. Our study highlights that @entity2 containing dressings found to be more effective in reducing @entity3 and improving the healing of PU.

title: Evaluation of effectiveness of hydrocolloid dressing vs XXXX containing dressing against pressure ulcers.

answer: @entity2


abstract: UNASSIGNED: @entity2 -dependent haloperoxidases (VHPOs) perform two-electron oxidation of @entity4 using @entity0 . Their mechanism, including the factors determining the substrate specificity and the pH- @entity1 of the catalytic rates, is poorly understood. The @entity3 cofactor in the active site of VHPOs contains "spectroscopically silent" V(V), which does not change oxidation state during the reaction. We employed an NMR crystallography approach based on @entity5 magic angle spinning NMR spectroscopy and Density Functional Theory, to gain insights into the structure and coordination environment of the cofactor in the resting state of @entity2 -dependent chloroperoxidases (VCPO). The cofactor environments in the wild type VCPO and its @entity6 / @entity7 / @entity8 mutant exhibiting 5-100 fold improved catalytic activity are examined at various pH values. Optimal sensitivity attained owing to the fast MAS probe technologies enabled the assignment of the location and number of protons on the @entity3 as a function of pH. The @entity3 cofactor changes its protonation from quadruply protonated at pH 6.3 to triply protonated at pH 7.3 to doubly protonated at pH 8.3. In contrast, in the mutant, the @entity3 protonation is the same at pH 5.0 and 8.3, and the cofactor is doubly protonated. This methodology to identify the distinct protonation environments of the cofactor, which are also pH dependent, could help explain the different reactivities of the wild type and mutant VCPO and their pH- @entity1 . This study demonstrates that (51)V-based NMR crystallography can be used to derive the detailed coordination environments of @entity2 centers in large biological molecules.

title: @entity5 NMR Crystallography of @entity2 Chloroperoxidase and its Directed Evolution @entity6 / @entity7 / XXXX Mutant: Protonation Environments of the Active Site.

answer: @entity8